Considering that increased IL6 rates have been associated with a severe prognosis in renal cell carcinoma patients [33], these results open new insights about the employment of tocilizumab or other related molecules for improving the outcome of such patients, potentially enhancing the effect of the other currently available immunotherapies. This evidence concerns the gene IL6 and renal cell carcinoma.